NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade

BACKGROUND: Melanoma is one of the few types of cancer with an increasing annual incidence. While a number of immunotherapies for melanoma have been associated with significant clinical benefit, including high-dose IL-2 and cytotoxic T lymphocyte antigen 4 (CTLA-4) blockade, clinical response to eit...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohlhapp, Frederick J, Broucek, Joseph R, Hughes, Tasha, Huelsmann, Erica J, Lusciks, Jevgenijs, Zayas, Janet P, Dolubizno, Hubert, Fleetwood, Vidyaratna A, Grin, Alisa, Hill, Graham E, Poshepny, Joseph L, Nabatiyan, Arman, Ruby, Carl E, Snook, Joshua D, Rudra, Jai S, Schenkel, Jason M, Masopust, David, Zloza, Andrew, Kaufman, Howard L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4437746/
https://www.ncbi.nlm.nih.gov/pubmed/25992289
http://dx.doi.org/10.1186/s40425-015-0063-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4437746/
https://www.ncbi.nlm.nih.gov/pubmed/25992289
http://dx.doi.org/10.1186/s40425-015-0063-3

Ejemplares similares